A subset of bone marrow stromal cells regulate ATP-binding cassette gene expression via insulin-like growth factor-I in a leukemia cell line

International Journal of Oncology

Volumn 45, Issue 4, 2014, Pages 1372-1380

  Benabou, Nadia ^a   Mirshahi, Pezhman ^a   Bordu, Camile ^a   Faussat, Anne Marie ^b   Tang, Ruoping ^b   Therwath, Amu ^a   Soria, Jeannette ^a   Marie, Jean Pierre ^b   Mirshahi, Massoud ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HÔPITAL SAINT ANTOINE   (France)

Author keywords

ATP binding cassette; Chemoresistance; Hospicells; IGF signaling pathway; Leukemia

Indexed keywords

ADENOSINE TRIPHOSPHATE; BREAST CANCER RESISTANCE PROTEIN; DAUNORUBICIN; DOXORUBICIN; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 3; MULTIDRUG RESISTANCE PROTEIN 1; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; ABC TRANSPORTER; IGF1R PROTEIN, HUMAN; PICROPODOPHYLLIN; PODOPHYLLOTOXIN; SOMATOMEDIN RECEPTOR;

ARTICLE; BONE MARROW STROMA CELL; CELL PROLIFERATION; COCULTURE; CONTROLLED STUDY; DRUG SENSITIVITY; GENE CASSETTE; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MICROENVIRONMENT; MULTIDRUG RESISTANCE; MYELOID LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; HL 60 CELL LINE; LEUKEMIA; MESENCHYMAL STROMA CELL; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE, TUMOR; CELL PROLIFERATION; DAUNORUBICIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HL-60 CELLS; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LEUKEMIA; MESENCHYMAL STROMAL CELLS; PODOPHYLLOTOXIN; RECEPTORS, SOMATOMEDIN;

EID: 84907468656     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2569     Document Type: Article

References (32)

1. Baudard M, Beauchamp-Nicoud A, Delmer A, Rio B, Blanc C, Zittoun R and Marie JP: Has the prognosis of adult patients with acute myeloid leukemia improved over years? A single institution experience of 784 consecutive patients over a 16-year period. Leukemia 13: 1481-1489, 1999.
2. Rafii A, Mirshahi P, Poupot M, Faussat AM, Simon A, Ducros E, Mery E, Couderc B, Lis R, Capdet J, Bergalet J, Querleu D, Dagonnet F, Fournié JJ, Marie JP, Pujade-Lauraine E, Favre G, Soria J and Mirshahi M: Oncologic trogocytosis of an original stromal cells induces chemoresistance of ovarian tumours. PLoS One 3: e3894, 2008.
3. Lis R, Capdet J, Mirshahi P, Lacroix-Triki M, Dagonnet F, Klein C, Mirshahi M, Fournié JJ, Rafii A and Poupot M: Oncologic trogocytosis with Hospicells induces the expression of N-cadherin by breast cancer cells. Int J Oncol 37: 1453-1461, 2010.
4. Benabbou N, Mirshahi P, Cadillon M, Soria J, Therwath A and Mirshahi M: Hospicells promote upregulation of the ATP binding cassette genes by insulin like growth factor-I via JAK2-STAT3 signaling pathway in ovarian cancer cell line. Int J Oncol 43: 685-694, 2013.
5. Pasquet M, Golzio M, Mery E, Rafii A, Benabbou N, Mirshahi P, Hennebelle I, Bourin P, Allal B, Teissie J, Mirshahi M and Couderc B: Hospicells (ascites-derived stromal cells) promote tumorigenicity and angiogenesis. Int J Cancer 126: 2090-2101, 2010.
6. Martinet L, Poupot R, Mirshahi P, Rafii A, Fournié JJ, Mirshahi M and Poupot M: Hospicells derived from ovarian cancer stroma inhibit T-cell immune responses. Int J Cancer 126: 2143-2152, 2010.
7. Castells M, Thibault B, Mery E, Golzio M, Pasquet M, Hennebelle I, Bourin P, Mirshahi M, Delord JP, Querleu D and Couderc B: Ovarian ascites-derived Hospicells promote angiogenesis via activation of macrophages. Cancer Lett 326: 59-68, 2012.
8. Mirshahi P, Rafii A, Vincent L, Berthaut A, Varin R, Kalantar G, Marzac C, Calandini OA, Marie JP, Soria C, Soria J and Mirshahi M: Vasculogenic mimicry of acute leukemic bone marrow stromal cells. Leukemia 23: 1039-1048, 2009.
9. Wu X, Tortolero-Luna G, Zhao H, Phatak D, Spitz MR and Follen M: Serum levels of insulin-like growth factor I and risk of squamous intraepithelial lesions of the cervix. Clin Cancer Res 9: 3356-3361, 2003. (Pubitemid 37082730)
10. Yang SY and Winslet M: The IGF system in carcinogenesis and its implication for cancer therapy. Curr Oncol 18: 301-302, 2011.
11. Samani AA, Yakar S, Le Roith D and Brodt P: The role ofhe IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 28: 20-47, 2007. (Pubitemid 46220849)
12. Héron-Milhavet L and LeRoith D: Insulin-like growth factor I induces MDM2-dependent degradation of p53 via the p38 MAPK pathway in response to DNA damage. J Biol Chem 277: 15600-15606, 2002. (Pubitemid 34967830)
13. He Y, Zhang J, Zheng J, Du W, Xiao H, Liu W, Li X, Chen X, Yang L and Huang S: The insulin-like growth factor-1 receptor kinase inhibitor, NVP-ADW742, suppresses survival and resistance to chemotherapy in acute myeloid leukemia cells. Oncol Res 19: 35-43, 2010.
14. Abe S, Funato T, Takahashi S, Yokoyama H, Yamamoto J, Tomiya Y, Yamada-Fujiwara M, Ishizawa K, Kameoka J, Kaku M, Harigae H and Sasaki T: Increased expression of insulin-like growth factor 1 is associated with Ara-C resistance in leukemia. Tohoku J Exp Med 209: 217-228, 2006. (Pubitemid 43905553)
15. Kuhn DJ, Berkova Z, Jones RJ, Woessner R, Bjorklund CC, Ma W, Davis RE, Lin P, Wang H, Madden TL, Wei C, Baladandayuthapani V, et al: Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. Blood 120: 3260-3270, 2012.
16. Guo YS, Jin GF, Houston CW, Thompson JC and Townsend CM Jr: Insulin-like growth factor-I promotes multidrug resistance in MCLM colon cancer cells. J Cell Physiol 175: 141-148, 1998. (Pubitemid 28140670)
17. Schwarze CP, Neu S, Beck J, Mavridou K, Ranke MB and Binder G: Influence of IGF-I and cell density on MDR1 expression in the T-lymphoblastoid cell line CCRF-CEM. Horm Res 52: 192-199, 1999. (Pubitemid 30145268)
18. Shimon I and Shpilberg O: The insulin-like growth factor system in regulation of normal and malignant hematopoiesis. Leuk Res 19: 233-240, 1995.
19. Doepfner KT, Spertini O and Arcaro A: Autocrine insulin-like growth factor-I signaling promotes growth and survival of human acute myeloid leukemia cells via the phosphoinositide 3-kinase/Akt pathway. Leukemia 21: 1921-1930, 2007. (Pubitemid 47299965)
20. Baier TG, Jenne EW, Blum W, Schönberg D and Hartmann KK: Influence of antibodies against IGF-I, insulin or their receptors on proliferation of human acute lymphoblastic leukemia cell lines. Leuk Res 16: 807-814, 1992.
21. Gilmore MJ, Prentice HG, Blacklock HA, Janossy G and Hoffbrand AV: A technique for rapid isolation of bone marrow mononuclear cells using Ficoll-Metrizoate and the IBM 2991 blood cell processor. Br J Haematol 50: 619-626, 1982. (Pubitemid 12155483)
22. Girnita A, Girnita L, del Prete F, Bartolazzi A, Larsson O and Axelson M: Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res 64: 236-242, 2004. (Pubitemid 38114104)
23. Qiang YW, Kopantzev E and Rudikoff S: Insulin like growth factor-I signaling in multiple myeloma: downstream elements, functional correlates, and pathway cross-talk. Blood 99: 4138-4146, 2002. (Pubitemid 35332058)
24. Rodon J, DeSantos V, Ferry RJ Jr and Kurzrock R: Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials. Mol Cancer Ther 7: 2575-2588, 2008.
25. Gregory CW, DeGeorges A and Sikes RA: The IGF axis in the development and progression of prostate cancer. Recent Res Dev Cancer 3: 437-462, 2001.
26. Macaulay VM: Insulin-like growth factors and cancer. Br J Cancer 65: 311-320, 1992.
27. Burren CP, Berka JL, Edmondson SR, Werther GA and Batch JA: Localization of mRNAs for insulin-like growth factor-I (IGF-I), IGF-I receptor, and IGF binding proteins in rat eye. Invest Ophthalmol Vis Sci 37: 1459-1468, 1996. (Pubitemid 26177322)
28. Clemmons DR and Maile LA: Integral membrane proteins that function coordinately with the insulin-like growth factor I receptor to regulate intracellular signaling. Endocrinology 144: 1664-1670, 2003. (Pubitemid 36543301)
29. Turner HE, Harris AL, Melmed S and Wass JA: Angiogenesis in endocrine tumors. Endocr Rev 24: 600-632, 2003. (Pubitemid 37330584)
30. Wu KD, Zhou L, Burtrum D, Ludwig DL and Moore MA: Antibody targeting of the insulin like growth factor I receptor enhances the anti-tumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis. Cancer Immunol Immunother 56: 343-357, 2007. (Pubitemid 46035904)
31. Karamouzis MV and Papavassiliou AG: Targeting insulin-like growth factor in breast cancer therapeutics. Crit Rev Oncol Hematol 84: 8-17, 2012.
32. Hopkins A, Crowe PJ and Yang JL: Effect of type 1 insulin-like growth factor receptor targeted therapy on chemotherapy in human cancer and the mechanisms involved. J Cancer Res Clin Oncol 136: 639-650, 2010.